China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its 9MW3811, an in-house developed IL-11 monoclonal antibody (mAb). The drug is intended for the treatment of various advanced malignant tumors and fibrotic diseases. It obtained clinical trial approval in Australia last month.
Mechanism of Action and Therapeutic Potential
9MW3811 is the first of its kind to enter clinical trials. It effectively blocks the activation of the downstream signal pathway of IL-11, thereby achieving a therapeutic effect on fibrosis and tumors. Studies have shown that IL-11 is up-regulated in invasive lung fibroblasts of patients with idiopathic pulmonary fibrosis. Additionally, IL-11 plays a role in the process of tumorigenesis, including cell proliferation, angiogenesis, and cell apoptosis.
Significance of the Approval
This approval marks a significant milestone in the development of 9MW3811, paving the way for further clinical trials and potential commercialization. Mabwell Bioscience’s continued innovation in the field of monoclonal antibodies highlights its commitment to advancing treatments for challenging medical conditions.-Fineline Info & Tech
